Week of October 29, 2012: Novartis to Construct New Biotechnology Facility in Singapore; Patheon to Acquire Banner Pharmacaps; and More - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of October 29, 2012: Novartis to Construct New Biotechnology Facility in Singapore; Patheon to Acquire Banner Pharmacaps; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

Novartis has announced the construction of a new biotechnology facility in Singapore with an investment of over $500 million. The new facility will focus on drug-substance manufacturing based on cell-culture technology, and will be colocated with the pharmaceutical production site in Tuas, Singapore. Read More

The CDMO Patheon has agreed to acquire Banner Pharmacaps, a specialty pharmaceutical business dedicated to the research, development, and manufacturing of gelatin-based dosage forms. The acquisition will be structured as a purchase of all of the shares of the entities through which Banner conducts its operations, for $255 million, subject to working capital and other adjustments. The acquisition is subject to applicable regulatory approvals and other customary terms and conditions, and is expected to close by the end of 2012. Read More

Pfenex has awarded Althea Technologies a contract for the cGMP manufacturing of circumsporozoite protein from plasmodium falciparum, a malaria antigen. Althea Technologies will implement the cGMP-ready Pfenex Expression Technology-based production process that was developed at Pfenex over the past several months. Processes for several additional malaria antigens are currently being developed at Pfenex. Read More

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here